FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 241 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $83,594 | +76.0% | 25,486 | +13.7% | 0.00% | – |
| Q3 2023 | $47,509 | -54.7% | 22,410 | +1.6% | 0.00% | -100.0% |
| Q2 2023 | $104,991 | -18.2% | 22,057 | -2.1% | 0.00% | 0.0% |
| Q1 2023 | $128,387 | -41.9% | 22,524 | +2.9% | 0.00% | -50.0% |
| Q4 2022 | $220,941 | -53.1% | 21,897 | +4.2% | 0.00% | -60.0% |
| Q3 2022 | $471,000 | -9.1% | 21,007 | +0.5% | 0.01% | 0.0% |
| Q2 2022 | $518,000 | -35.3% | 20,906 | +1.2% | 0.01% | -16.7% |
| Q1 2022 | $801,000 | -33.2% | 20,651 | +0.8% | 0.01% | -33.3% |
| Q4 2021 | $1,199,000 | -1.3% | 20,495 | +0.0% | 0.01% | -10.0% |
| Q3 2021 | $1,215,000 | -31.4% | 20,492 | +0.5% | 0.01% | -28.6% |
| Q2 2021 | $1,770,000 | +5.7% | 20,394 | +0.4% | 0.01% | -6.7% |
| Q1 2021 | $1,675,000 | -8.6% | 20,317 | +0.8% | 0.02% | -11.8% |
| Q4 2020 | $1,832,000 | +144.3% | 20,148 | +7.4% | 0.02% | +142.9% |
| Q3 2020 | $750,000 | +60.3% | 18,753 | +37.4% | 0.01% | 0.0% |
| Q2 2020 | $468,000 | +48.6% | 13,649 | -3.9% | 0.01% | +40.0% |
| Q1 2020 | $315,000 | – | 14,197 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |